Combination of C1-INH and lung surfactant for the treatment...

Details Combination of C1-INH and lung surfactant for the treatment... Combination of C1-INH and lung surfactant for the treatment...

2006-05-30

2006-05-30

Weber, Jon (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S350000, C436S013000, C424S278100

Reexamination Certificate

active

07053176

ABSTRACT:
Pharmaceutical composition for the treatment of infant respiratory distress syndrome and acute lung injury (including adult respiratory distress syndrome) which contains C1 esterase inhibitor (C1-INH) and lung surfactant which comprises a lung surfactant protein.

REFERENCES:
patent: 5891844 (1999-04-01), Häfner
patent: 6051224 (2000-04-01), Strayer et al.
patent: 6129934 (2000-10-01), Egan et al.
patent: 32 29 179 (1994-02-01), None
patent: 0 055 041 (1982-06-01), None
patent: 0 100 910 (1984-02-01), None
patent: 0 101 935 (1984-03-01), None
patent: 0 110 498 (1984-06-01), None
patent: 0 119 056 (1984-09-01), None
patent: 0 145 005 (1985-06-01), None
patent: 0 251 449 (1988-01-01), None
patent: 0 286 011 (1988-10-01), None
patent: 0 348 967 (1990-01-01), None
patent: 0 368 823 (1990-05-01), None
patent: 0 406 732 (1991-01-01), None
patent: WO 86/03408 (1986-06-01), None
patent: WO 87/06943 (1987-11-01), None
patent: WO 89/04326 (1989-05-01), None
patent: 90/07469 (1990-07-01), None
patent: WO 91/00871 (1991-01-01), None
patent: WO 91/18015 (1991-11-01), None
patent: 92/22320 (1992-12-01), None
patent: WO 95/32992 (1995-12-01), None
patent: 96/09831 (1996-04-01), None
patent: 96/09831 (1996-04-01), None
patent: WO 97/26863 (1997-07-01), None
patent: WO 97/35882 (1997-10-01), None
patent: 98/35683 (1998-08-01), None
patent: WO 98/49191 (1998-11-01), None
Salvatierra, A. et al. (1997) C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am J Respir Crit Care Med. vol. 155, pp. 1147-1154.
Gauthier, M. et al. (1997) Reactivation of C1-inhibitor polymers by denaturation and gel-filtration chromatography. Anal Biochem. vol. 248, pp. 228-233.
Attchment 1 (2003) “Develops its surfactant as an inhalable aerosol that retains critical therapeutic properties” pp. 1-3.
Attchment 2 (2003) “Meaning of liposome” p. 1.
Vangerow, B., et al., “Effects of C1-Inhibitor and rSP-C surfactant on oxygenation and histology in rats with lavage-induced acute lung injury”, 19thInternational Symposium on Intensive Care and Emergency Medicine, Brussels, Mar. 16-19, 1999, Poster Presentation.
Vangerow, B., et al'., “Effects of C1-Inhibitor and rSP-C surfactant on oxygenation and histology in rats with lavage-induced acute lung injury”,Critical Care, The Official Journal of the Critical Care Forum, Abstracts of Posters, Editor: Jean-Louis Vincent, vol. 3, Supp. 1, Mar. 1999.
Possmayer, Fred, et al., “Calcium-Protein-Lipid Interactions in Pulmonary Surfactant”. Prog. Resp. Res., vol. 18, pp. 112-120, 1984.
Maunder, Richard J., et al., “Clinical Risks Associated with the Adult Respiratory Distress Syndrome”; chapter 1 of Zapol, Lemaire eds., “Adult Respiratory Distress Syndrome”, Marcel Dekker Inc., 1991.
Walmrath, D., et al., “Therapy in ARDS”Intensivmedizin und Notfallmedizin, vol. 36, No. 2, pp 104-125, (1999) XP-000856579.
Friedman, Lawrence S., et al., “Harrison's Principles of Internal Medicine, 14thEdition”. 284, Peptic Ulcer and Related Disorders, 2000.
Schuster, Daniel P., “What is Acute Lung Injury? What is ARDS?”. Chest 1995; 107; 1721-1726.
Lachmann, B., et al., “Exogenous surfactant therapy in adults”. Atemw.-Lungenkrkh. 1993, 19: 581-591.
Gregory, T.J., et al., “Survanta® Supplementation in Patients with Acute Respiratory Syndrome (ARDS)”. Am. J. Respir. Crit. Care Med., 1994, 149: A567.
Abraham, Edward, et al., “Liposomal prostaglandin E1in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial”. Crit. Care Med. 1996, 24: 10-15.
Bernard, Gordon R., et al., “High-Dose Corticosteroids in Patients with the Adult Respiratory Distress Syndrome”. N.Engl.J. Med. 1987, 317: 1565-1570.
Thiel, M., et al., “The role of polymorphonuclear leukocytes in the pathogenesis of the adult respiratory distress syndrome”. Anaesthesist 1996, 45: 113-130. (English Abstract on 114).
Rice, Glenn C., et al., “Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid”. Proc. Natl. Acad. Sci. USA 1994, 91: 3857-3561.
Fisher, Charles J., et al., “Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome”. JAMA 1994, 271: 1836-1843.
Goerke, Jon, “Lung Surfactant”. J. Biochem. Biophys. Acta 1974, 344: 241-261.
King, R.J., et al., “Physiological Correlations . . . ”. Am. J. Physiol. 1972, 223: 715-726.
Häfner, Dietrich, et al., “Effects of rSP-C Surfactant on Oxygenation and Histology in a Rat-Lung-Lavage Model of Acute Lung Injury”. Am. J. Respir. Crit. Care Med. 1998, 158: 270-278.
Gommers, D., et al., “Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS)”. Intensive Care Med. 1998, 24: 494-500.

Affiliated with

Also associated with

Rating

Combination of C1-INH and lung surfactant for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination of C1-INH and lung surfactant for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of C1-INH and lung surfactant for the treatment... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3595741